Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion To MS In Patients With First Clinical Signs Of The Disease
Links shared publicly online about this topic.
- 773total visits
Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion To MS In Patients With First Clinical Signs Of The Disease
Merck Serono, a division of Merck KGaA,Darmstadt, Germany, announced that the two-year Phase III REFLEX 1 study met its primary endpoint by demonstrating that Rebif® (interferon beta-1a) signi
View full resource at medicalnewstoday.com
Tags: Multiple Sclerosis Medication, Disease and Condition, Avonex, Rebif, Merck & Co., disease
Most Recently Shared on October 27, 2010 at 4:16 am By:
Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion To MS In Patients With First Cli... http://bit.ly/czROF3
Also Shared By:
: Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of the Disease | wallstreet:online
wallstreet-online.de — “GENEVA, October 25, 2010 /PRNewswire/ - Study Met its Primary Endpoint - Risk of Converting to Multiple Sclerosis (McDonald Criteria) Was Reduced by Half in Patients Treated With Rebif(R) 44 mcg Three Times a Week Merck Serono, a division of ...” View full resource at wallstreet-online.de
Most Recently Shared on October 25, 2010 at 1:38 pm By:
Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First ...... http://bit.ly/bV9uRH
Advertisement
MNT Multiple Scl
@mnt_multiplescl
Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion To MS In Patients With First Clinica... http://mnt.to/3LJJ
1 year ago...